Research Topics
Genomes and Genes | C BonnySummaryAffiliation: Centre Hospitalier Universitaire Vaudois Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
IB1 reduces cytokine-induced apoptosis of insulin-secreting cellsC Bonny
Division of Medical Genetics and the Department of Internal Medicine, CHUV University Hospital, 1011 Lausanne Switzerland
J Biol Chem 275:16466-72. 2000..These data indicate that IB1 plays an anti-apoptotic function in insulin-producing cells probably by controlling the activity of the JNK signaling pathway...- Blocking stress signaling pathways with cell permeable peptidesChristophe Bonny
Unit of Molecular Genetics, CHUV Lausanne, Switzerland
Adv Exp Med Biol 588:133-43. 2006..We will discuss how we may interfere with MAPK signaling by using short cell-permeable peptides able to block, through a competitive mechanisms, relevant protein-protein contacts, and their effects on signaling and cell function... - Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell deathC Bonny
Division of Medical Genetics, Centre Hospitalier Universitaire Vaudois University Hospital, Lausanne, Switzerland
Diabetes 50:77-82. 2001..These data establish these bioactive cell-permeable peptides as potent pharmacological compounds that decrease intracellular JNK signaling and confer long-term protection to pancreatic beta-cells from IL-1beta-induced apoptosis... - [Role of intracellular signalling pathways in the development of type 1 diabetes]Christophe Bonny
Unité de Génétique Moléculaire, Service de Genetique Medicale, CHUV, 1011 Lausanne
Rev Med Suisse 1:1153-6. 2005..The pivotal role that the insulin-secreting cells play in their own destruction starts to be uncovered, and these new mechanisms are the target for a whole battery of future drugs... - cDNA cloning and mapping of a novel islet-brain/JNK-interacting proteinS Negri
Division of Medical Genetics, CHUV University Hospital, Lausanne, 1011, Switzerland
Genomics 64:324-30. 2000..These data establish IB2 as a novel scaffold protein that regulates the JNK signaling pathway in brain and pancreatic beta-cells and indicate that IB2 represents a novel candidate gene for diabetes... 
The transcriptional repressor REST determines the cell-specific expression of the human MAPK8IP1 gene encoding IB1 (JIP-1)A Abderrahmani
Department of Internal Medicine, CHUV University Hospital, Lausanne, Switzerland
Mol Cell Biol 21:7256-67. 2001..Taken together, these data establish a critical role for REST in the control of the tissue-specific expression of the human IB1 gene...- The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetesG Waeber
Department of Internal Medicine, CHUV University Hospital, Lausanne, Switzerland
Nat Genet 24:291-5. 2000..Identification of this novel non-maturity onset diabetes of the young (MODY) form of diabetes demonstrates that IB1 is a key regulator of 3-cell function... - Characterization of the promoter region of the mouse Xist geneN Pillet
Unit of Molecular Genetics, University of Lausanne, Switzerland
Proc Natl Acad Sci U S A 92:12515-9. 1995..A third region from -82 to -41 is needed for correct expression. Deletion of the segment -441 to -231 is associated with an increase in CAT activity and may represent a silencer element... - Genomic organization, fine-mapping, and expression of the human islet-brain 1 (IB1)/c-Jun-amino-terminal kinase interacting protein-1 (JIP-1) geneV Mooser
Department of Pathology, CHUV University Hospital, Lausanne, CH 1011, Switzerland
Genomics 55:202-8. 1999..Our data indicate that the sequence and expression pattern of IB1 are highly conserved between rodent and human and provide the necessary tools to investigate whether IB1 is involved in human diseases... - IB1, a JIP-1-related nuclear protein present in insulin-secreting cellsC Bonny
Department of Internal Medicine B, University Hospital, Lausanne, Switzerland
J Biol Chem 273:1843-6. 1998..These data demonstrate that IB1 is a DNA-binding protein related to JIP-1, which is highly expressed in pancreatic beta-cells where it functions as a transactivator of the GLUT2 gene... - The loss of GLUT2 expression in the pancreatic beta-cells of diabetic db/db mice is associated with an impaired DNA-binding activity of islet-specific trans-acting factorsC Bonny
Department of Internal Medicine B 19 135, University Hospital, CHUV, Lausanne, Switzerland
Mol Cell Endocrinol 135:59-65. 1997..These data suggest that the decreased activity of GTIIa, in contrast to PDX-1, may be a major initial step in the development of the beta-cell dysfunction in this model of diabetes... - Methylation status of CpG sites and methyl-CpG binding proteins are involved in the promoter regulation of the mouse Xist geneN Allaman-Pillet
Division of Medical Genetics and Unit of Molecular Genetics, CHUV, Lausanne, Switzerland
Gene Expr 7:61-73. 1998..Therefore, we suggest that Xist repression involves its promoter methylation and two distinct methylated DNA binding proteins... - The 5' repeat elements of the mouse Xist gene inhibit the transcription of X-linked genesN Allaman-Pillet
Division of Medical Genetics, CHUV, Lausanne, Switzerland
Gene Expr 9:93-101. 2000..This Xcr effect on X-linked genes suggests that Xcr transcript recognizes the genes to be silenced and is involved in the spreading of X inactivation... 
JNK3 is abundant in insulin-secreting cells and protects against cytokine-induced apoptosisS Abdelli
Service of Medical Genetics, CHUV Hospital, Chemin des Falaises 1, 1011, Lausanne, Switzerland
Diabetologia 52:1871-80. 2009..This report aims to characterise the expression and role in apoptosis of the three JNK isoforms in insulin-secreting cells exposed to cytokines...- Genomic characterization and embryonic expression of the mouse Bigh3 (Tgfbi) geneD F Schorderet
Division Autonome de Génétique Médicale, CHUV, 1101 Lausanne, Switzerland
Biochem Biophys Res Commun 274:267-74. 2000..The characterization of the murine structure is a prerequisite for the making of such models... - Circadian regulation of islet genes involved in insulin production and secretionN Allaman-Pillet
Service of Medical Genetics and Unit of Molecular Genetics, Centre Hospitalier Universitaire Vaudois CHUV, CH 1011 Lausanne, Switzerland
Mol Cell Endocrinol 226:59-66. 2004..The circadian deregulation of these genes could therefore participate in the diabetic state development... - Transcriptional activation of the GLUT2 gene by the IPF-1/STF-1/IDX-1 homeobox factorG Waeber
Department of Internal Medicine B, University Hospital, Lausanne, Switzerland
Mol Endocrinol 10:1327-34. 1996..These data demonstrate that the murine GLUT2 promoter is controlled by the PDX-1 homeobox factor through the identified GLUT2TAAT motif... - A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivoGiuseppina Milano
Departments of Cardiovascular Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Am J Physiol Heart Circ Physiol 292:H1828-35. 2007..01). In conclusion, d-JNKI-1 is an important compound that can be used in preclinical models to investigate the role of JNK signaling in vivo. Inhibition of JNK during I/R is cardioprotective in anesthetized rats in vivo... - Inhibition of the c-Jun N-terminal kinase-mediated mitochondrial cell death pathway restores auditory function in sound-exposed animalsJing Wang
INSERM U 583, 80 rue Augustin Fliche, 34295 Montpellier, France
Mol Pharmacol 71:654-66. 2007..Blocking this signaling pathway with RWM delivery of d-JNKI-1 may have significant therapeutic value as a therapeutic intervention to protect the human cochlea from the effects of sound trauma... - Blocking c-Jun-N-terminal kinase signaling can prevent hearing loss induced by both electrode insertion trauma and neomycin ototoxicityAdrien A Eshraghi
Cochlear Implant Research Program, University of Miami Ear Institute, Department of Otolaryngology, University of Miami Miller School of Medicine, 1600 NW 10th Avenue, RMSB 3160, Miami, FL 33136 1015, USA
Hear Res 226:168-77. 2007..This unique therapeutic approach may have clinical application for preventing: (1) hearing loss caused by neomycin ototoxicity; and (2) the progressive component of electrode insertion trauma-induced hearing loss... - Novel strategy for treatment of viral central nervous system infection by using a cell-permeating inhibitor of c-Jun N-terminal kinaseJ David Beckham
Department of Medicine, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA
J Virol 81:6984-92. 2007..Given the efficacy of the inhibitor in protecting mice from viral encephalitis, JNK inhibition represents a promising and novel treatment strategy for viral encephalitis... - Glucose and leptin induce apoptosis in human beta-cells and impair glucose-stimulated insulin secretion through activation of c-Jun N-terminal kinasesKathrin Maedler
Larry L Hillblom Islet Research Center, University of California, Los Angeles, California, USA
FASEB J 22:1905-13. 2008..Therefore, JNK inhibition may protect beta-cells from the deleterious effects of high glucose and leptin in diabetes... - D-JNKI-1 treatment prevents the progression of hearing loss in a model of cochlear implantation traumaAdrien A Eshraghi
Department of Otolaryngology, University of Miami Ear Institute, Miami, Florida 33136-1015, USA
Otol Neurotol 27:504-11. 2006..CONCLUSION: Hearing loss caused by cochlear implant electrode insertion trauma in guinea pigs has both acute and delayed components. The delayed component can be prevented by treating the cochlea with D-JNKI-1... - Brief reoxygenation episodes during chronic hypoxia enhance posthypoxic recovery of LV function: role of mitogen-activated protein kinase signaling pathwaysSandrine Morel
Department of Cardiology, University of Lausanne, CHUV, BH10 1011, Lausanne, Switzerland, and Department of Cardiac Surgery, Alder Hey Royal Children Hospital, Liverpool, UK
Basic Res Cardiol 101:336-45. 2006..Brief normoxic episodes during chronic hypoxia prevent p38-MAPK activation and restore posthypoxic recovery of myocardial function... - A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenanceZhi-Ye Zhuang
Department of Anesthesiology, Pain Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Neurosci 26:3551-60. 2006..Targeting the JNK pathway in spinal astroglia may present a new and efficient way to treat neuropathic pain symptoms... - A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemiaTiziana Borsello
Institut de Biologie Cellulaire et de Morphologie, Universite de Lausanne, Rue du Bugnon 9, CH 1005, Switzerland
Nat Med 9:1180-6. 2003..Protection correlated with prevention of an increase in c-Jun activation and c-Fos transcription. In view of its potency and long therapeutic window, this protease-resistant peptide is a promising neuroprotective agent for stroke... - A unique set of SH3-SH3 interactions controls IB1 homodimerizationOle Kristensen
Biostructural Research, Department of Medicinal Chemistry, The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
EMBO J 25:785-97. 2006..Taken together, these results indicate that IB1 homodimerization through its SH3 domain has pleiotropic effects including regulation of the insulin secretion process... - Targeting the JNK pathway as a therapeutic protective strategy for nervous system diseasesChristophe Bonny
, Lausanne, Switzerland
Rev Neurosci 16:57-67. 2005.... - Calcium- and proteasome-dependent degradation of the JNK scaffold protein islet-brain 1Nathalie Allaman-Pillet
Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, CH 1011 Lausanne, Switzerland
J Biol Chem 278:48720-6. 2003..These data indicate that calcium influx initiated by cytokines mediates ubiquitination and degradation of IB1/JIP1 and may, therefore, provide a link between calcium influx and JNK-mediated apoptosis in pancreatic beta-cells... - Use of cell-permeable peptides to prevent neuronal degenerationTiziana Borsello
IBCM, University of Lausanne, Lausanne, Switzerland
Trends Mol Med 10:239-44. 2004..Here, the recent findings that highlight the potential of this approach for therapeutic application are reviewed... - D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemiaLorenz Hirt
Service de Neurologie, CHUV, Lausanne, Switzerland
Stroke 35:1738-43. 2004..In 2 models of severe ischemic injury, we have evaluated the neuroprotective action of D-JNKI1, a cell-penetrating and protease-resistant peptide selectively inhibiting the c-Jun-N-terminal kinase (JNK)... - Intracellular stress signaling pathways activated during human islet preparation and following acute cytokine exposureSaida Abdelli
Service of Medical Genetics, 1011 Lausanne-CHUV, Switzerland
Diabetes 53:2815-23. 2004..Therefore, strategies might be rationally developed to avoid possible synergistic activation of these pathways in mediating islet loss during isolation and following grafting... - Antitumorigenic effect of proteasome inhibitors on insulinoma cellsJoachim Størling
DMSc, Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
Endocrinology 146:1718-26. 2005..Our findings demonstrate that proteasome inhibitors possess antitumorigenic and antiinsulinogenic effects on insulinoma cells... - A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cellsDavid Michod
Department of Cellular Biology and Morphology, Lausanne University, Switzerland
Oncogene 23:8971-8. 2004..Our results demonstrate the feasibility in enhancing the efficacy of currently used drugs to selectively kill cancer cells using peptides derived from pro-apoptotic caspase substrate fragments... - Homogeneous and nonradioactive high-throughput screening platform for the characterization of kinase inhibitors in cell lysatesSylvie Guenat
Service of Medical Genetics, CHUV, Lausanne, Switzerland
J Biomol Screen 11:1015-26. 2006.... - Profiling treatment-specific post-translational modifications in a complex proteome with subtractive substrate phage displayAngela Tenzer
Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland
Proteomics 4:2796-804. 2004..Novel, selected peptide substrates were investigated in vitro and in vivo and showed high substrate specificity and functional biological significance... - Induction of apoptosis in human corneal and HeLa cells by mutated BIGH3Sabine Morand
Division of Medical Genetics, and Unit of Oculogenetics, Sion, Switzerland
Invest Ophthalmol Vis Sci 44:2973-9. 2003..This work suggests that apoptosis is a key element in the pathophysiology of BIGH3-related corneal dystrophies... - Crystallization and preliminary crystallographic characterization of an SH3 domain from the IB1 scaffold proteinImran Dar
Structural Chemistry Group, Department of Medicinal Chemistry, Danish University of Pharmaceutical Sciences, Universitetsparken 2, DK-2100, Denmark
Acta Crystallogr D Biol Crystallogr 59:2300-2. 2003..These crystals are orthorhombic (P2(1)2(1)2(1)), with unit-cell parameters a = 45.9, b = 57.0, c = 145.5 A. These are the first crystallographic data on a scaffold molecule such as IB1 to be reported... - Cell-permeable peptides induce dose- and length-dependent cytotoxic effectsAlessandra K Cardozo
The Laboratory of Experimental Medicine, Universite Libre de Bruxelles, Route de Lennik 808, B 1070 Brussels, Belgium
Biochim Biophys Acta 1768:2222-34. 2007.... - Modulation of the c-Jun N-terminal kinase activity in the embryonic heart in response to anoxia-reoxygenation: involvement of the Ca2+ and mitoKATP channelsAlexandre Sarre
Department of Physiology, Faculty of Biology and Medicine, University of Lausanne, 7 rue du Bugnon, 1005 Lausanne, Switzerland
Mol Cell Biochem 313:133-8. 2008....